|
Pancreatic Neoplasm
|
0.900 |
GeneticVariation
|
disease |
LHGDN |
Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer.
|
17659731 |
2007 |
|
Pancreatic Neoplasm
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
This study was undertaken to evaluate the impact of wild-type or mutant p53 status on the synergistic effects of 5-Fluorouracil (5-FU) and radiation (XRT) in pancreatic tumors.
|
12014658 |
2002 |
|
Pancreatic Neoplasm
|
0.900 |
GeneticVariation
|
disease |
LHGDN |
Pancreatic tumor cell lines, CRL1420, which contains elevated levels of mutant p53, and CRL1682, with no detectable p53 protein, were stably transfected with the exogenous wild-type p53 gene.
|
17651038 |
2007 |
|
Pancreatic Neoplasm
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
One out of seven Tsc1 (-/-) ; p53 (-/-) animals developed pancreatic tumors showing a distinctive tumor morphology, reminiscent of human ACC.
|
26683340 |
2015 |
|
Pancreatic Neoplasm
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Gene therapy approaches involving p53 replacement are promising due to the central role of p53 in the cellular response to DNA damage and the high incidence of p53 mutations in pancreatic tumors.
|
10505853 |
1999 |
|
Pancreatic Neoplasm
|
0.900 |
GeneticVariation
|
disease |
LHGDN |
Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations.
|
18701504 |
2008 |
|
Pancreatic Neoplasm
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Both K-ras and p53 gene mutations are found commonly in pancreatic tumors.
|
10217065 |
1999 |
|
Pancreatic Neoplasm
|
0.900 |
GeneticVariation
|
disease |
LHGDN |
Detecting low-abundance p16 and p53 mutations in pancreatic juice using a novel assay: heteroduplex analysis of limiting dilution PCRs.
|
17106238 |
2006 |
|
Pancreatic Neoplasm
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Mutation of the p53 tumor suppressor gene is found in a large number of exocrine pancreatic tumors.
|
9436856 |
1998 |
|
Pancreatic Neoplasm
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, the identical nucleotide mutation of TP53 gene was observed from both the endometrial and pancreatic tumors.
|
18577117 |
2008 |
|
Pancreatic Neoplasm
|
0.900 |
GeneticVariation
|
disease |
LHGDN |
Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy.
|
15846069 |
2005 |
|
Pancreatic Neoplasm
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Surprisingly, little is known about the role and regulation of hdm2 in pancreatic tumors, a large proportion (50-75%) of which contain mutant p53.
|
19029954 |
2009 |
|
Pancreatic Neoplasm
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Among other somatic mutations, TP53 is mutated in more than 75% of human pancreatic tumors.
|
29367463 |
2018 |
|
Pancreatic Neoplasm
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Owing to the high incidence of p53 mutations in PanIN 3 lesions and pancreatic tumors, we interrogated the comparative ability of adult pancreatic acinar and ductal cells to respond to oncogenic Kras and mutant Tp53(R172H) using Hnf1b:CreER(T2) and Mist1:CreER(T2) mice.
|
26592447 |
2016 |
|
Pancreatic Neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations.
|
24875860 |
2014 |
|
Pancreatic Neoplasm
|
0.900 |
Biomarker
|
disease |
CTD_mouse |
Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma.
|
26390243 |
2015 |
|
Pancreatic Neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
This suggests that LKB1-induced apoptosis is p53 independent but might be p73-mediated in the pancreatic tumor cell line, AsPC-1.
|
14511408 |
2004 |
|
Pancreatic Neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
Treatment of nude mice with the retroviral p53 vector resulted in a significant inhibition of growth of the primary pancreatic tumor, as well as the peritoneal tumor deposits, compared with the LXSN control vector.
|
9706132 |
1998 |
|
Pancreatic Neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
Supernumerary and abnormal centrosomes are observed in the earliest stages of pancreatic tumor development, and the p53 pathway acts as an initial barrier to the proliferation of cells with extra centrosomes.
|
29491046 |
2018 |
|
Pancreatic Neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
Collectively, these findings reveal a highly dynamic and interdependent metabolic, transcriptional, and epigenetic regulatory network governed by Yap, Myc, Sox2, and p53 that dictates pancreatic tumor metabolism, growth, survival, and differentiation.
|
31447265 |
2019 |
|
Pancreatic Neoplasm
|
0.900 |
Biomarker
|
disease |
HPO |
|
|
|
|
Pancreatic Neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
This is the first time that concomitant point mutations in c-N-ras and p53 have been found in a neuroendocrine pancreatic tumor.
|
9042254 |
1997 |
|
Pancreatic Neoplasm
|
0.900 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Pancreatic Neoplasm
|
0.900 |
Biomarker
|
disease |
CTD_mouse |
Functions of TAp63 and p53 in restraining the development of metastatic cancer.
|
23873029 |
2014 |
|
Pancreatic Neoplasm
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
With the aid of a newly developed target unmasking fluid (TUF), p53 overexpression was visualized by immunohistochemistry on recent and archival paraffin-embedded tissue samples of colon, stomach, and pancreas neoplasms.
|
8434637 |
1993 |